AstraZeneca has teamed up with the Flanders Institute for Biotechnology and the Centre for Drug Design and Discovery to make a play for inhibitors of MALT1. The announcement caps five years of progress toward validating MALT1 in B cell lymphoma and autoimmune diseases.